ResMed Inc. (NYSE:RMD) is expected to pay $0.33 on Dec 15, 2016. The indicated annual dividend is $1.32. Shareholders owning the stock before Nov 8, 2016 will be eligible to receive the payout. Based on ResMed Inc.’s current price of $57.42, the dividend is 0.57%. This dividend’s record date is Nov 10, 2016 and the announcement date is Oct 26, 2016. The stock increased 0.14% or $0.08 on November 4, hitting $57.42. ResMed Inc. (NYSE:RMD) has declined 1.31% since April 5, 2016 and is downtrending. It has underperformed by 3.26% the S&P500.
ResMed Inc. is a holding company. The Company, through its subsidiaries, designs, makes and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The company has a market cap of $8.01 billion. The Firm develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories. It has a 23.3 P/E ratio. The Firm owns interest in Inova Labs Inc., a medical device firm specializing in the development and commercialization of oxygen therapy products.
Insitutional Activity: The institutional sentiment decreased to 1.44 in Q2 2016. Its down 0.01, from 1.45 in 2016Q1. The ratio dropped, as 42 funds sold all ResMed Inc. shares owned while 87 reduced positions. 36 funds bought stakes while 150 increased positions. They now own 83.87 million shares or 2.40% more from 81.90 million shares in 2016Q1.
Nationwide Fund Advsr has 237,862 shares for 0.07% of their US portfolio. Ameritas Partners Inc holds 0.09% or 22,201 shares in its portfolio. Leavell Investment Management holds 0.07% of its portfolio in ResMed Inc. (NYSE:RMD) for 7,800 shares. Credit Suisse Ag has 0.02% invested in the company for 272,300 shares. Highbridge Capital Mgmt Ltd Liability accumulated 171,142 shares or 0.18% of the stock. West Coast Financial Limited Liability Company reported 75,749 shares or 1.73% of all its holdings. Retirement System Of Alabama has invested 0.07% of its portfolio in ResMed Inc. (NYSE:RMD). Rhumbline Advisers last reported 307,997 shares in the company. Shell Asset Management Communications last reported 67,100 shares in the company. Chatham Cap Grp reported 19,795 shares or 0.39% of all its holdings. Bessemer Gru Inc holds 800 shares or 0% of its portfolio. Hussman Strategic Inc last reported 0.02% of its portfolio in the stock. Taylor Frigon Cap Management Ltd Liability Co last reported 24,897 shares in the company. Capital Investors holds 0.13% of its portfolio in ResMed Inc. (NYSE:RMD) for 7.92M shares. Gateway Inv Advisers Ltd Liability Corp last reported 0.04% of its portfolio in the stock.
Insider Transactions: Since May 16, 2016, the stock had 0 buys, and 25 insider sales for $22.27 million net activity. The insider Farrell Michael J. sold 5,975 shares worth $388,554. FARRELL PETER C had sold 20,000 shares worth $1.27M on Tuesday, July 5. Shares for $127,285 were sold by Hollingshead James. Sandercock Brett sold 35,000 shares worth $2.47M. Shares for $1.71 million were sold by WAREHAM JOHN P on Monday, August 8. Shares for $2.53M were sold by SULPIZIO RICHARD on Wednesday, August 10. TAYLOR RONALD R sold $1.43 million worth of ResMed Inc. (NYSE:RMD) on Tuesday, August 16.
ResMed Inc. (NYSE:RMD) Ratings Coverage
Out of 11 analysts covering ResMed Inc (NYSE:RMD), 4 rate it a “Buy”, 3 “Sell”, while 4 “Hold”. This means 36% are positive. ResMed Inc has been the topic of 17 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The stock of ResMed Inc. (NYSE:RMD) has “Neutral” rating given on Wednesday, April 27 by Piper Jaffray. On Friday, September 25 the stock rating was upgraded by Goldman Sachs to “Buy”. Needham maintained it with “Buy” rating and $66 target price in Sunday, August 16 report. The firm earned “Hold” rating on Thursday, December 17 by Needham. The rating was upgraded by Bank of America to “Buy” on Thursday, September 29. The stock of ResMed Inc. (NYSE:RMD) earned “Underweight” rating by Barclays Capital on Thursday, April 7. The firm has “Underweight” rating by Barclays Capital given on Tuesday, January 19. The stock has “Underperform” rating given by Needham on Monday, June 27. The rating was downgraded by Jefferies to “Underperform” on Tuesday, August 23. The firm has “Neutral” rating given on Thursday, April 28 by Macquarie Research.
More news for ResMed Inc. (NYSE:RMD) were recently published by: Prnewswire.com, which released: “ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2017” on October 25, 2016. Forbes.com‘s article titled: “Ex-Dividend Reminder: Pfizer, ResMed and EverBank Financial” and published on November 04, 2016 is yet another important article.
RMD Company Profile
ResMed Inc., incorporated on March 31, 1994, is a holding company. The Company, through its subsidiaries, designs, makes and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The Firm develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.